🔗 Share this article

While the United States proceeds with historic changes to its vaccine schedules, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by questioning Covid vaccinations during the global health crisis and has focused upon potential fatalities after COVID-19 vaccination in her short tenure at the FDA.

Scheduled Overhauls to Childhood Immunization Program

Agency leaders had intended to announce sweeping revisions to the pediatric immunization program earlier this month, bringing the US with the Danish national calendar, sources say – a substantial departure that would put the US out of alignment with a large portion of the international standard with no evidence for improved outcomes. This reveal has been pushed back until the new year.

Instead of Vinay Prasad, Høeg is set to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this calendar year.

A Shift at the FDA

The acting appointment might represent a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has frequently advocated for halting some pediatric immunization guidelines in the US in order to be more similar to Denmark's approach, a society with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

So far public appearances, she has kept her attention on immunizations – usually the domain of Prasad, director of the FDA’s CBER – rather than drug regulation.

Questions Over Qualifications

Dr. Høeg has no obvious experience in pharmaceutical research, oversight or leadership, which has been customary for previous leaders of the CBER. She has been employed at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a major agency. She lacks background in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the research of medication creation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that former directors who headed CBER have had.”

The drug center has an vast workload at the agency, Woodcock pointed out.

“Many people just focuses on the new drug program, but the generic drug division authorizes numerous generic drugs. There’s a biologic copycat branch, OTC medication office and other areas, and each of these have to be supervised,” Woodcock explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant leadership element to the position, which manages more than 5,000 staff members. “It’s a massive leadership role, if you execute it properly,” the former official concluded.

Official Statement and Disputed Programs

Regarding concerns about Høeg’s credentials and whether this assignment indicates greater collaboration among FDA leaders on vaccines, a press secretary said that the “questions are based on flawed premises”.

“Her experience aligns with the responsibilities of her job,” the representative explained, citing the months Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the commissioner’s new expedited review system, a controversial expedited therapy clearance system that apparently worried her predecessors. “How are these drugs being picked for this expedited pathway? Who takes the decisions?” Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards less stringent rules of most medications, except for immunizations.”

Public History on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if problematic, history, critics observe. She released a research paper using unconfirmed public submissions to assess the rate of heart inflammation following Covid immunization. She advised the state of Florida surgeon general Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are more dangerous than they are.

Part of her “policy goals” for the incoming federal leadership encompassed altering regulations for new vaccines and halting “optional” vaccines, she stated following the vote on a audio program. At the agency, Høeg has allegedly suggested preventing teenage boys from receiving Covid vaccinations.

“She is an thorough true believer who begins with her conclusions and reverse-engineers to accommodate the science in a very misleading, fraudulent manner,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow skeptics, {like|